Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Ivana Magovcevic-Liebisch
AddedFeb 19, 2024
UpdatedMay 31, 2026
Ivana Magovcevic-Liebisch

Ivana Magovcevic-Liebisch

Board Member, Spyre Therapeutics

CrunchbaseThe Org

Ivana Magovcevic-Liebisch's Career

Spyre Therapeutics
Spyre Therapeutics

Austin, TX, US

Board Member· Board
Absci
Absci

Vancouver, WA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Ivana Magovcevic-Liebisch's Career

Spyre Therapeutics
Spyre Therapeutics
Public$266M692013Austin, TX, US
Board Member· Board

Leadership at Spyre Therapeutics

Cameron TurtleCameron TurtleCEO
David LoweDavid LoweFounder
Alison LawtonAlison LawtonBoard Member
Laurie StelzerLaurie StelzerBoard Member
Russell J. CoxRussell J. CoxBoard Member

Similar to Spyre Therapeutics

Precision IBDPrecision IBDEncinitas, CA, USTherapeuticsest. 2016Precision IBDEncinitas, CA, US · est. 2016

Precision IBD: A biotech firm specializing in developing precise therapeutics for bowel diseases.

Series A · $13.8M30
Spyryx BiosciencesSpyryx BiosciencesDurham, NC, USTherapeuticsest. 2013Spyryx BiosciencesDurham, NC, US · est. 2013

US-based Spyryx Biosciences pioneers next-gen therapeutics for obstructive lung diseases since 2013.

Series A · $18.2M30
Osprey Pharmaceuticals USAOsprey Pharmaceuticals USASan Francisco, CA, USTherapeuticsest. 1998Osprey Pharmaceuticals USASan Francisco, CA, US · est. 1998

Osprey Pharmaceuticals USA: Innovating protein therapeutics for inflammatory and immune diseases.

Series A · $29.7M30
SphynKx TherapeuticsSphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

Seed · $50k30
Absci
Absci
Public$237.9M1932011Vancouver, WA, US
Board Member· Board

Leadership at Absci

Bryan LawlisBryan LawlisBoard Member
Zach JonassonZach JonassonBoard Member
Dan RabinovitsjDan RabinovitsjBoard Member
Gustavo MahlerGustavo MahlerBoard Member
Sean McClainSean McClainBoard Member
Frans van HoutenFrans van HoutenBoard Member

Ivana Magovcevic-Liebisch's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Ivana Magovcevic-Liebisch

Bill BrodieBill BrodieCEO · Vigilant BiosciencesKris NarayanKris NarayanBoard Member · MediKarmaMark HousleyMark HousleyBoard Member · VigilentSanjay GuptaSanjay GuptaCEO · BioVigilMatthew KimMatthew KimCo-Founder · Vigilant BiosciencesGerard ElderingGerard ElderingBoard Member · Blue Vigil